Francesca Palandri, MD, PhD

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Predictors of response have a significant effect on clinical decision-making because they may help oncologists select the best treatment for specific patients.

Delaying treatment with ruxolitinib by more than a year leads to decreased response rates and overall survival in patients with myelofibrosis.